By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Cadence
Pharmaceuticals, Inc. et al. v. Fresenius Kabi USA, LLC
3:13-cv-00139;
filed January 17, 2013 in the Southern District of California

• Plaintiffs: 
Cadence Pharmaceuticals, Inc.; SCR Pharmatop
• Defendant: 
Fresenius Kabi USA, LLC

Infringement
of U.S. Patent Nos. 6,028,222 ("Stable Liquid Paracetamol Compositions,
and Method for Preparing the Same," issued February 22, 2000) and
6,992,218 ("Method for Obtaining Aqueous Formulations of
Oxidation-Sensitive Active Principles," issued January 31, 2006), both
licensed to Cadence, following a Paragraph IV certification as part of
Fresenius' filing of an ANDA to manufacture a generic version of Cadence's
Ofirmev® (acetaminophen injection, used for the management of mild to moderate
pain, the management of moderate to severe pain with adjunctive opioid
analgesics, and the reduction of fevers). 
View the complaint here.

Bioprojet SCR
v. Kappos
1:13-cv-00055;
filed January 14, 2013 in the Eastern District of Virginia

Review and
correction of the patent term adjustment calculation made by the U.S. Patent
and Trademark Office for U.S. Patent No. 8,222,294 ("Combinations of an
Anti Emetic Agent and an Enkephalinase Inhibitor," issued July 17, 2012).  View the complaint here.

Wyeth LLC et
al. v. Kappos
1:13-cv-00049;
filed January 10, 2013 in the Eastern District of Virginia

• Plaintiffs:
Wyeth LLC; Janssen Alzheimer Immunotherapy
• Defendant:
Hon. David J. Kappos

Review and
correction of the patent term adjustment calculation made by the U.S. Patent
and Trademark Office for U.S. Patent No. 8,227,403 ("A-β Immunogenic
Peptide Carrier Conjugates and Methods of Producing Same," issued July 24,
2012).  View the complaint here.